Acorda jumps after Amaya panel

Acorda Therapeutics Inc. (NASDAQ:ACOR) gained $7.91 (47%) to $24.65 on Thursday after an FDA panel voted 12-1 on Wednesday that the company demonstrated the effectiveness of Amaya fampridine-SR to improve walking in patients with multiple sclerosis (See BioCentury Extra, Wednesday, Oct. 14, 2009). ...